Cardiac Success

Cardiac Success is a medical device company founded in 2017 in Yokneam, Israel, within the Alon Medtech Ventures incubator, by serial entrepreneur Dr. Shimon Eckhouse (Chairman) and Dr. David Neustadter (CTO). The company is developing the Vsling — an innovative transcatheter ventricular repair device designed to treat Heart Failure with Reduced Ejection Fraction (HFrEF), a condition affecting 1.85 million symptomatic US patients and millions more worldwide who fail to respond to guideline-directed medical therapy. The Vsling is an atraumatic, size-adjustable implant delivered via a low-profile transcatheter delivery system that directly reshapes the left ventricle by cinching the papillary muscle bases, halting the pathological cycle of cardiac remodeling and initiating heart recovery. The device is based on proven surgical papillary muscle approximation procedures but enables a minimally invasive transcatheter approach. Currently in a focused First-in-Human clinical study in Israel, Poland, and Georgia, the Vsling has shown promising early results in improving patient quality of life and cardiac function. Cardiac Success raised a $5.2 million Series A financing in 2021 led by 415 Capital, and has received EU Horizon Europe research funding.